Introduction {#s2}
============

By the end of 2009, an estimated 33 million people were living with HIV, the vast majority in sub-Saharan Africa and Asia. Tuberculosis (TB) remains the most common cause of death in people living with HIV. Compared to people without HIV, people living with HIV have a more than 20-fold increased risk of developing TB [@pmed.1000391-Getahun1]. TB disease may occur at any stage of HIV disease and is frequently the first recognized presentation of underlying HIV infection [@pmed.1000391-Sonnenberg1],[@pmed.1000391-Havlir1]. Without antiretroviral treatment (ART), up to 50% of people living with HIV who are diagnosed with TB die during the 6--8 mo of TB treatment [@pmed.1000391-Mukadi1]--[@pmed.1000391-Lawn1]. This risk increases to 72%--98% among those with multi-drug (MDR) or extensively drug-resistant (XDR) TB [@pmed.1000391-Gandhi1],[@pmed.1000391-Wells1]. Although ART can reduce the incidence of TB both at individual [@pmed.1000391-Badri1] and population [@pmed.1000391-Miranda1] levels, people living with HIV on ART still have higher TB incidence rates and a higher risk of dying from TB [@pmed.1000391-Lawn2]. Routine TB screening offers the opportunity to diagnose and promptly treat TB disease, and to identify those without TB disease who may be eligible for TB preventive therapy [@pmed.1000391-Burgess1]. The use of TB preventive therapy can reduce TB incidence and is therefore of considerable benefit to patients [@pmed.1000391-Akolo1].

For these reasons, the World Health Organization (WHO) recommends regular screening for active TB disease of all people living with HIV and providing either treatment for active disease or isoniazid preventive therapy (IPT) to mitigate TB morbidity, mortality, and transmission [@pmed.1000391-WHO1]. However, in 2009, of the estimated 33 million people living with HIV, only 1.7 million (5%) were screened for TB, and about 85,000 (0.2%) were offered IPT [@pmed.1000391-WHO2]. Currently there is no internationally accepted evidence-based tool to screen for TB in people living with HIV. Several studies have shown that the presenting signs and symptoms of TB in people living with HIV are different from those in people without HIV to diagnose TB; for example, many people living with HIV who have culture-confirmed TB do not report having a prolonged cough, which is one of the standard TB screening questions used by national TB control programs globally [@pmed.1000391-Reid1]. Moreover, the most widely available TB diagnostic tests such as smear microscopy and chest radiography perform poorly among people living with HIV; because most people living with HIV and TB have either sputum acid-fast bacilli (AFB) smear negative pulmonary or extrapulmonary TB [@pmed.1000391-Getahun2].

We conducted an individual participant data meta-analysis of published and unpublished studies to develop a simple, standardized TB screening rule for resource-constrained settings that will adequately separate patients into two groups: (1) those for whom TB is reliably excluded, and IPT and ART, if indicated, can be initiated; and (2) those who require further investigation for TB disease. We describe the results of this meta-analysis and propose an algorithm for TB screening among people living with HIV in resource-constrained settings.

Methods {#s3}
=======

We proceeded through several steps. First, we prospectively enumerated criteria for studies to be included in our meta-analysis. Second, we searched for and selected studies that met these criteria. Third, we sought primary data from investigators and mapped individual-level data to common symptoms. Fourth, we identified five symptoms available in most studies and, within each study, computed the sensitivity and specificity of 23 screening rules derived from these five symptoms. Finally, we used meta-analysis methods to estimate the performance of all 23 rules, as well as the association of study-level and individual-level correlates with performance.

Inclusion of Studies {#s2a}
--------------------

We defined studies as being eligible for inclusion in this analysis if they met the following criteria: (1) collected sputum specimens from people living with HIV regardless of signs or symptoms; (2) used mycobacterial culture of at least one specimen to diagnose TB; and (3) collected data about signs and symptoms.

Search Strategy and Selection of Studies {#s2b}
----------------------------------------

To identify studies eligible for the meta-analysis, we conducted a systematic literature review of studies related to TB screening among people living with HIV in June 2008 using PubMed and various combinations of the following keywords: "HIV," "Tuberculosis," "TB screening," "Smear-negative TB," "Sputum negative TB," "TB case finding," "Intensified TB case finding," "Isoniazid prevention treatment, trial or therapy." We also searched for abstracts presented at conferences organized by the International Union Against TB and Lung Diseases and the International AIDS Society between 2000--2008. No language restriction was placed on the search. We reviewed all retrieved titles and abstracts for relevance to the topic. The reference lists of retrieved studies were also reviewed to identify further studies that meet the eligibility criteria. In addition, recognized experts in the field were contacted to identify studies that were not available (e.g., unpublished) in the initial electronic search. Studies that involve concomitant HIV testing and mycobacterial culture on all patients are resource intensive and challenging to implement in countries with a high burden of TB and HIV. Therefore, we believe it is unlikely that eligible studies would have been completed but missed by our search strategy.

We found 2,119 publications and reviewed all their abstracts. Using the criteria above, we selected 53 for review of the full text. Twenty-one articles included information on signs and symptoms for TB screening in people living with HIV. A total of 14 studies (six published and eight unpublished at the time of the search) met the inclusion criteria of our meta-analysis ([Figure 1](#pmed-1000391-g001){ref-type="fig"}). The corresponding authors or principal investigators were contacted for all 14 studies to confirm that their studies met all the eligibility criteria. One unpublished dataset was excluded for not meeting the inclusion criteria after verification with the principal investigator, and another one was excluded because the investigators could not submit the data within the agreed timeframe. A total of 12 investigators (representing six published and six unpublished studies at the time of the search) provided de-identified individual patient data for inclusion in the primary meta-analysis within an agreed time framework ([Table 1](#pmed-1000391-t001){ref-type="table"}) [@pmed.1000391-Ayles1]--[@pmed.1000391-Chheng1]. In November 2010, immediately preceding manuscript publication, we re-ran the search strategy again to look for additional studies that were reported since the initial search and should have been included in the meta-analysis. The search found seven eligible studies, of which all except one [@pmed.1000391-Bassett1] were included in our meta-analysis as unpublished datasets.

![Search strategy and studies included in the meta-analysis (PRISMA flow diagram).](pmed.1000391.g001){#pmed-1000391-g001}
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###### Summary of studies included in the meta-analysis.

![](pmed.1000391.t001){#pmed-1000391-t001-1}

  Reference                                                                                                             Study Population Characteristics (Setting, Continent, n Samples, Culture Method Used)                                                                   Sample Size   PLTB/PLHIV[a](#nt101){ref-type="table-fn"} (%)   PLTB/PLHIV (%) with Data on the Five Symptoms
  ----------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ------------------------------------------------ -----------------------------------------------
  Ayles et al. 2009                                                                           Adults of more than 15 y of age sampled from one rural and one urban communities in Zambia (community, sub-Saharan Africa, 1 LJ and MGIT).                                           8,044                      43/2,253 (1.9)                                  41/2,145 (1.9)
  Corbett et al. 2010[b](#nt102){ref-type="table-fn"}                                 Random sample of adults in 46 previously enumerated neighbourhoods in the high density suburbs of Harare, Zimbabwe (community, sub-Saharan Africa, 3 LJ).                                   10,079                      31/1,841 (1.7)                                  31/1,834 (1.7)
  Cain et al. 2010                                                         PLHIV from 8 outpatient clinics in Cambodia, Thailand, and Vietnam who were enrolled regardless of signs or symptoms suggestive of TB (clinical, Southeast Asia, 3 MGIT and LJ).                        1,748                     267/1,724 (15.5)                                267/1,721 (15.5)
  Day et al. 2006                                                                              Employees of a gold mining company first attending the TB preventive therapy clinic in South Africa (miners, sub-Saharan Africa, 2 LJ).                                             1,093                       32/991 (3.2)                                      0/0 (--)
  Corbett et al. 2007[b](#nt102){ref-type="table-fn"}                                                           Employees of 22 small and medium-sized enterprises in Zimbabwe (community, sub-Saharan Africa, 3 LJ).                                                              4,668                       3/797 (0.4)                                      3/797 (0.4)
  Lewis et al. 2009[b](#nt102){ref-type="table-fn"}                         All consenting employees of a gold mining indusry who undergo annual medical examinations in an occupational health centre in South Africa (miners, sub-Saharan Africa, 2 LJ).                         1,955                       18/560 (3.2)                                    18/560 (3.2)
  Shah et al. 2009                                                          All newly diagnosed HIV-positive clients of at least 18 y old from the VCT Clinic in a large referral hospital in Addis Ababa, Ethiopia (clinical, sub-Saharan Africa, 1 LJ).                           453                        27/427 (6.3)                                    22/357 (6.2)
  Kimerling et al. 2002                                                                        PLHIV of at least 15 y of age and enrolled in an HIV home-based care service in Phnom Penh, Cambodia (community, Southeast Asia, 1 LJ).                                              441                        36/393 (9.2)                                    36/393 (9.2)
  Lawn et al. 2009                                                                          PLHIV with more than 18 y of age who were referred to a community-based ART service in South Africa (clinical, sub-Saharan Africa, 2--4 MGIT).                                          235                       58/226 (25.7)                                    57/218 (26.1)
  Wood et al. 2007                                                                       Randomly sampled and consenting adults living in shacks in a high-density residential area in South Africa (community, Sub-Saharan Africa, 4 MGIT).                                        174                        12/163 (7.4)                                      0/0 (--)
  Mohammed et al. 2004                                   PLHIV with WHO clinical stage 3 or 4 disease referred for possible participation in a trial of TB-preventive therapy in 3 hospital-based adult HIV clinics in South Africa (clinical, sub-Saharan Africa, 1 BACTEC).       129                        10/128 (7.8)                                      0/0 (--)
  Chheng et al. 2008                                                    All consenting participants of more than 19 y old who were tested for HIV in a Voluntary Counseling Center and referred for TB screening in Cambodia (clinical, Southeast Asia, 3 LJ).                      504                       20/123 (16.3)                                    20/123 (16.3)
  Total                                                                                                                                                                                                                                                                           29,523                     557/9,626 (5.8)                                  495/8,148 (6.1)

The following patients were excluded: (1) patients who were on TB treatment or prophylaxis at enrolment; (2) patients who were smear positive, but culture grew non- tuberculosis mycobacterium (NTM); and (3) patients who were smear positive, but culture negative.

Patients were previously screened for TB before enrolment into the study.

LJ, Lowenstein-Jensen culture medium; MGIT, Mycobacterial Growth Indicator Tube culture system; PLHIV, persons living with human immunodeficiency virus; PLTB, persons with tuberculosis disease; VCT, voluntary counselling and testing for HIV.

Investigators for all included studies signed a data sharing and confidentiality agreement, and agreed to a data management, analysis, and publication plan. During design and analysis phases of the meta-analysis, the investigators of the studies and data managers of the included studies held multiple discussions by email, by teleconference, and in person in Geneva, Switzerland and Atlanta, Georgia, United States.

Data Abstraction and Management {#s2c}
-------------------------------

The list of variables from the most comprehensive dataset [@pmed.1000391-Cain1] was used to construct an initial master list of variables. All the variables from each study included in the meta-analysis were mapped to this master list. Principal investigators and data managers for the 12 studies worked with the meta-analysis investigators to ensure accurate mapping of data from the primary studies to the master variable list. In the end, the final dataset of the meta-analysis included 159 variables that appeared in at least two of the studies. We identified five symptoms common to most studies and limited the meta-analysis to the nine studies with substantially complete information for those five symptoms.

Case Definitions {#s2d}
----------------

We defined a TB patient as any person living with HIV and at least one specimen culture positive for *Mycobacterium tuberculosis* (MTB). We defined participants as having no TB if cultures were negative for MTB and participants were judged not to have TB on the basis of the original study definition of the investigators. We excluded from the analysis: (1) patients who were receiving treatment for TB (infection or disease) at enrolment; (2) patients who were AFB smear positive, but whose culture grew non-tuberculous mycobacteria; and (3) patients who were AFB smear positive or scanty, but sputum culture negative.

Sources of Study Heterogeneity {#s2e}
------------------------------

All studies were reviewed to identify study-level characteristics that could substantially impact the findings of the meta-analysis. Two studies were conducted exclusively among gold miners living in South Africa [@pmed.1000391-Day1],[@pmed.1000391-Lewis1], a population that may not be broadly generalizable, because of its demographics, its high prevalence of non-TB illnesses (e.g., silicosis) that can produce cough, and the practice of annual TB radiological screening. Five studies [@pmed.1000391-Ayles1],[@pmed.1000391-Corbett1],[@pmed.1000391-Corbett2],[@pmed.1000391-Kimerling1],[@pmed.1000391-Wood1] were conducted among individuals drawn from a community setting through prevalence surveys, which may lead to enrolment of patients with a different spectrum of TB and HIV disease than would be found among patients seeking care. Three studies [@pmed.1000391-Corbett1],[@pmed.1000391-Corbett2],[@pmed.1000391-Lewis1] involved participants who were previously screened for TB or who had had access to routine TB screening before being enrolled into the studies. Finally, three studies exclusively used liquid media to culture specimens [@pmed.1000391-Lawn3]--[@pmed.1000391-Mohammed1], two studies used both solid and liquid media [@pmed.1000391-Ayles1],[@pmed.1000391-Cain1], and seven studies exclusively used solid media ([Table 1](#pmed-1000391-t001){ref-type="table"}). Liquid media have substantially increased sensitivity for growing MTB, particularly in patients with low levels of TB bacilli, as would be expected in a population of people living with HIV being screened for TB [@pmed.1000391-Cruciani1]. Studies that used liquid media, therefore, would have improved ability to classify patients correctly into those who have TB and those who do not. We explored the impact of these factors on the performance of the screening algorithms and analyzed subsets of the final dataset grouped according to these characteristics.

Data Analysis {#s2f}
-------------

We compared characteristics of patients with TB to those of patients without TB to derive a standardized rule for TB screening among people living with HIV. The goal of TB screening is to divide the population of people living with HIV into two groups: (1) those who do not have TB; and (2) those who need further evaluation for the diagnosis of TB (i.e., TB suspects). We restricted our analysis to clinical symptoms that could be readily assessed at any level of the health system and that were asked about in all studies: current cough (C), haemoptysis (H), fever (F), night sweats (S), and weight loss (W). Using the four studies that included chest radiography data [@pmed.1000391-Cain1],[@pmed.1000391-Lewis1],[@pmed.1000391-Shah1],[@pmed.1000391-Lawn3], we also evaluated the impact of adding abnormal chest radiography findings to the TB screening rule. Only observations with no missing data for the symptoms of interest were included in the analysis.

We considered "1-of-*n*" rules as candidates for screening for TB that could best classify patients into two groups (not TB and suspected TB) with high sensitivity [@pmed.1000391-Cain1]. The "1" represents the minimum number of symptoms that must be present in an individual to be classified as a suspected TB patient and the "*n*" represents the number of symptom(s) in a given rule. For example, a "1-of-3" rule could be a set of symptoms such as current cough, fever, and weight loss, abbreviated here as CFW. An individual with at least one symptom specified in this particular rule would be classified as a TB suspect; an individual without any of these symptoms would be classified as not having TB. We considered all combinations of the five candidate symptoms except for combinations that include both current cough and haemoptysis, yielding a total of 23 candidate rules: two 1-of-4 rules (CFSW, HFSW), seven 1-of-3 rules (CFS, CFW, CSW, HFS, HFW, HSW, FSW), nine 1-of-2 rules (CF, CS, CW, HF, HS, HW, FS, FW, SW), and five 1-of-1 rules (C, H, F, S, W) (see also [Table 3](#pmed-1000391-t003){ref-type="table"}.) The analysis with abnormal chest radiographic findings (X) considered these 23 rules, each augmented with this additional sign (e.g., CFSWX).

Other analyses have considered *m*-of-*n* rules with *m*\>1 [@pmed.1000391-Cain1]. These rules cannot exceed the sensitivity of 1-of-*n* rules. Suppose that a positive screen requires the presence of at least two symptoms out of current cough, fever, and night sweats, the number of true positives for this 2-of-3 rule will not be greater than the number of true positives from the corresponding 1-of-3 rules. Because our aim in this analysis was to identify the most sensitive rule, we did not include rules of this kind in our analysis.

We applied two closely related methods for cross-study analysis of sensitivity and specificity of these 23 candidate screening rules: bivariate random-effects meta-analysis (BREMA) and the hierarchical summary relative operating characteristic (HSROC) curve [@pmed.1000391-Harbord1],[@pmed.1000391-Reitsma1]. BREMA jointly models sensitivity and specificity while accommodating between-study heterogeneity, and HSROC models tradeoffs between sensitivity and specificity across study populations. Both methods can be unified in the same model. In addition to sensitivity and specificity, we calculated predictive value negative and likelihood ratio negative of each candidate rule [@pmed.1000391-Grimes1]. Our goal was to identify a combination of symptoms that achieved the highest possible sensitivity and the lowest possible negative likelihood ratio for ruling out TB disease (without any predetermined cut-off points).

To further understand between-study heterogeneity and other factors associated with the diagnostic performance of the most sensitive rule, we analyzed several study-level predictors (setting, prior screening of study participants, culture medium used, and geographic region) and participant-level predictors (age, gender, CD4 T-lymphocyte cell count \[CD4\], and abnormal chest radiographic findings). Our analytic methods produced odds ratios that reflect the magnitude of association between each factor and the probability of correctly identifying persons with TB (sensitivity) or without TB (specificity). For a range of TB prevalence values, we calculated the negative predictive values at levels of each covariate. We calculated the ratio of the number of patients that screen positive but who actually have no TB (false positives) and hence unnecessarily require additional TB diagnostic evaluation (e.g., culture) to the number of patients that screen positive and actually have TB (true positives), which is referred to as the number needed to screen. We calculated this ratio for different rules using a theoretical population of 1,000 people living with HIV with different levels of TB prevalence. This ratio provides proxy information similar to a marginal cost-effectiveness analysis for different screening rules and it helps quantify how much a health program would need to invest (as measured by additional diagnostic tests) for every patient with TB identified through the screening rule [@pmed.1000391-Reilly1].

Each observation with a missing covariate value was omitted from analysis of that covariate. BREMA models were fitted using SAS procedure Glimmix (SAS 9.22, SAS Institute), and further calculations were performed in R (R 2.10.1, R Development Core Team).

Ethical Review {#s2g}
--------------

All data collection included in the meta-analysis was approved by institutional ethical review boards at the respective institutions during the original study; if necessary, principal investigators requested additional approval from institutional review boards for the inclusion of the primary dataset in the meta-analysis. All data for the meta-analysis were provided completely de-identified. In the meta-analysis dataset, investigators were not able to link case records to individuals.

Results {#s4}
=======

Investigators provided data about 29,523 participants, of whom 10,057 were people living with HIV. The dataset included 9,626 people living with HIV who had TB screening and sputum culture performed, of whom 8,148 could be evaluated on the five symptoms of interest from nine of 12 studies ([Figure 2](#pmed-1000391-g002){ref-type="fig"}).

![Flow chart of study participants included in the individual patient data meta-analysis.](pmed.1000391.g002){#pmed-1000391-g002}

Most patients (77% \[7,386/9,626\]) were from sub-Saharan Africa; the rest were from Southeast Asian countries. The median age was 34 y (interquartile range \[IQR\], 27--41 y). Of the 9,626 patients with HIV in the 12 studies, CD4 cell count information was available for 3,489 (36%) and chest radiography information for 3,903 (41%). The median CD4 count was 248 cells/µl (IQR, 107--409).

The overall prevalence of TB disease was 5.8% (557/9,626), ranging across studies from 0.4% to 25.7% ([Table 1](#pmed-1000391-t001){ref-type="table"}). More than half of TB patients (52% \[288/557\]) had sputum smear negative pulmonary TB, whereas 39% (218/557) had sputum smear positive pulmonary, and 5% (28/557) had exclusively extrapulmonary TB. The anatomic site of TB was not specified in 4% (23/557) of patients.

[Table 2](#pmed-1000391-t002){ref-type="table"} summarizes the distribution of common variables, and [Table S1](#pmed.1000391.s002){ref-type="supplementary-material"} summarizes how each question was actually asked in each study. Because duration of cough was included in many studies but was asked about in different ways, we were able to analyze data using three different cough variables: cough in the past 4 wk (information available for 39.3% of participants); cough lasting for 2 wk or more (information available for 47.1%); and cough present in the last 24 h, which is referred to as "current cough" (information available for 89.6%).

10.1371/journal.pmed.1000391.t002

###### Characteristics of participants with and without TB for variables included in the analysis.

![](pmed.1000391.t002){#pmed-1000391-t002-2}

  Characteristic                                                       All PLHIV (*n = *9,626)   PLHIV with Data on the Five Symptoms (*n = *8,148)                  
  ------------------------------------------------------------------- ------------------------- ---------------------------------------------------- --------------- --------------
  **Origin of patient**                                                                                                                                              
  Sub-Saharan Africa                                                        7,152 (78.9)                             234 (42.0)                       5,739 (75.0)     172 (34.8)
  Southeast Asia                                                            1,917 (21.1)                             323 (58.0)                       1,914 (25.0)     323 (65.2)
  **Setting**                                                                                                                                                        
  Clinical                                                                  2,246 (24.8)                             382 (68.5)                       2,053 (26.8)     366 (73.9)
  Community                                                                 5,322 (58.7)                             125 (22.4)                       5,058 (66.1)     111 (22.4)
  Miners                                                                    1,501 (16.5)                              50 (9.0)                          542 (7.1)       18 (3.6)
  **Sex**                                                                                                                                                            
  Male                                                                      4,957 (54.7)                             356 (63.9)                       3,811 (49.8)     309 (62.4)
  Female                                                                    4,111 (45.3)                             201 (36.1)                       3,841 (50.2)     186 (37.6)
  Missing or not recorded                                                      1 (0.0)                                0 (0.0)                            1 (0.0)        0 (0.0)
  **Median age (IQR),** ***n = *** **8,633 (7,286)**                         34 (27--41)                            33 (28--40)                        33 (27--40)    32 (28--39)
  **Median CD4+ count (IQR),** ***n = *** **3,489 (2,409)**                268 (126--427)                          106 (38--241)                      229 (94--391)   94 (33--215)
  **Cough in the past 4 wk**                                                                                                                                         
  Yes                                                                       1,439 (15.9)                             303 (54.4)                       1,270 (16.6)     278 (56.2)
  No                                                                        1,909 (21.0)                             129 (23.2)                       1,067 (13.9)     110 (22.2)
  Missing or not recorded                                                   5,721 (63.1)                             125 (22.4)                       5,316 (69.5)     107 (21.6)
  **Cough lasting for 2 wk or more**                                                                                                                                 
  Yes                                                                        957 (10.6)                              197 (35.4)                        848 (11.1)      177 (35.8)
  No                                                                        3,093 (34.1)                             288 (51.7)                       2,046 (26.7)     260 (52.5)
  Missing or not recorded                                                   5,019 (55.3)                             72 (12.9)                        4,759 (62.2)     58 (11.7)
  **Haemoptysis**                                                                                                                                                    
  Yes                                                                         543 (6.0)                              60 (10.8)                          523 (6.8)      58 (11.7)
  No                                                                        8,509 (71.4)                             495 (88.9)                       7,130 (93.2)     437 (88.3)
  Missing or not recorded                                                     17 (0.2)                                2 (0.4)                            0 (0.0)        0 (0.0)
  **Current cough or cough in the past 24 h**                                                                                                                        
  Yes                                                                       1,625 (17.9)                             274 (49.2)                       1,530 (20.0)     260 (52.5)
  No                                                                        6,474 (71.4)                             250 (44.9)                       6,123 (80.0)     235 (47.5)
  Missing or not recorded                                                    970 (10.7)                               33 (5.9)                           0 (0.0)        0 (0.0)
  **Current fever or fever in the past 4 wk**                                                                                                                        
  Yes                                                                       1,801 (19.9)                             294 (52.8)                       1,669 (21.8)     280 (56.6)
  No                                                                        7,002 (77.2)                             246 (44.2)                       5,984 (78.2)     215 (43.4)
  Missing or not recorded                                                     266 (2.9)                               17 (3.0)                           0 (0.0)        0 (0.0)
  **Current night sweats or night sweats in the past 4 wk**                                                                                                          
  Yes                                                                       1,710 (18.9)                             242 (43.4)                       1,497 (19.6)     225 (45.4)
  No                                                                        7,329 (80.8)                             313 (56.2)                       6,156 (80.4)     270 (54.6)
  Missing or not recorded                                                     30 (0.3)                                2 (0.4)                            0 (0.0)        0 (0.0)
  **Current weight loss or weight loss in the past 4 wk**                                                                                                            
  Yes                                                                       2,434 (26.8)                             333 (59.8)                       2,258 (29.5)     308 (62.2)
  No                                                                        6,478 (71.4)                             218 (39.1)                       5,395 (70.5)     187 (37.8)
  Missing or not recorded                                                     157 (1.7)                               6 (1.1)                            0 (0.0)        0 (0.0)
  **Abnormal chest radiography**                                                                                                                                     
  Yes                                                                         581 (6.4)                              271 (48.7)                         294 (3.8)      239 (48.3)
  No                                                                        2,900 (32.0)                             151 (27.1)                       2,155 (28.1)     145 (29.3)
  Missing or not recorded                                                   5,588 (61.6)                             135 (24.2)                       5,204 (68.0)     111 (22.4)
  **Abnormal chest radiography consistent with TB**                                                                                                                  
  Yes                                                                         377 (4.2)                              227 (40.8)                         261 (3.4)      209 (42.2)
  No                                                                        2,589 (28.5)                             144 (25.8)                       1,641 (21.4)     129 (26.1)
  Missing or not recorded                                                   6,103 (67.3)                             186 (33.4)                       5,751 (75.2)     157 (31.7)
  **Any one of current cough, fever, night sweats, or weight loss**                                                                                                  
  Yes                                                                       3,591 (39.6)                             425 (76.3)                       3,563 (46.6)     418 (84.4)
  No                                                                        4,090 (45.1)                             77 (13.8)                        4,090 (53.4)     77 (15.6)
  Not evaluable                                                             1,388 (15.3)                              55 (9.9)                           0 (0.0)        0 (0.0)

We analyzed the performance of individual and combinations of symptoms as screening rules using data from the 8,148 participants who could be evaluated based on the five candidate symptoms. [Table 3](#pmed-1000391-t003){ref-type="table"} shows the diagnostic performance characteristics for the 23 candidate combinations of symptoms, sorted from highest sensitivity to lowest. The most sensitive rule was the presence of any one of the following symptoms: current cough, fever, night sweats, and weight loss (CFSW). The population-average sensitivity of this symptom combination was 78.9% (95% confidence interval \[CI\] 58.3%--90.9%) with the negative likelihood ratio of 0.426 (95% CI 0.349--0.520), which corresponds to a postscreening reduction in the probability of TB by 15%--20% [@pmed.1000391-Grimes1].

10.1371/journal.pmed.1000391.t003

###### Diagnostic performance of 23 candidate 1-of-*n* rules.

![](pmed.1000391.t003){#pmed-1000391-t003-3}

  Rule    Sensitivity (95% CI)               Specificity (95% CI)               LRN (95% CI)                         
  ------ ---------------------- ---------------------------------------------- -------------- -------------- ------- ----------------
  CFSW            78.9                           (58.3--90.9)                       49.6       (29.2--70.1)   0.426   (0.349--0.520)
  HFSW            75.7           (53.9--89.2)[a](#nt105){ref-type="table-fn"}       52.7       (31.8--72.7)   0.461   (0.391--0.544)
  CFW             74.0           (51.7--88.3)[a](#nt105){ref-type="table-fn"}       53.8       (32.8--73.6)   0.483   (0.416--0.561)
  CSW             73.4                           (51.0--88.0)                       53.8       (32.8--73.5)   0.494   (0.428--0.570)
  CFS             73.1                           (50.6--87.9)                       61.1       (39.7--79.0)   0.440   (0.382--0.506)
  HFW             70.6                           (47.5--86.4)                       57.5       (36.2--76.4)   0.511   (0.454--0.576)
  FSW             69.2                           (45.9--85.6)                       55.7       (34.5--75.0)   0.554   (0.497--0.617)
  HSW             68.1                           (44.6--85.0)                       58.7       (37.3--77.2)   0.544   (0.492--0.602)
  CW              65.3                           (41.6--83.3)                       60.3       (38.8--78.4)   0.576   (0.530--0.625)
  CF              65.0                           (41.3--83.1)                       68.6       (47.7--83.9)   0.510   (0.470--0.553)
  HFS             63.7                           (39.9--82.3)                       66.3       (45.2--82.4)   0.548   (0.509--0.589)
  FW              63.1                           (39.3--81.9)                       61.4       (40.0--79.1)   0.601   (0.560--0.644)
  SW              61.0                           (37.2--80.5)                       61.9       (40.5--79.5)   0.630   (0.594--0.669)
  CS              59.7                           (35.9--79.6)                       69.4       (48.7--84.4)   0.581   (0.551--0.613)
  HW              56.8                           (33.3--77.6)                       66.8       (45.7--82.8)   0.647   (0.620--0.675)
  FS              56.3                           (32.8--77.3)                       70.1       (49.6--84.9)   0.623   (0.598--0.649)
  HF              52.0                           (29.2--74.1)                       75.0       (55.6--87.7)   0.640   (0.620--0.660)
  W               49.3                           (27.0--71.9)                       71.1       (50.8--85.5)   0.712   (0.693--0.733)
  F               42.8                           (22.2--66.3)                       79.8       (62.4--90.4)   0.716   (0.695--0.738)
  HS              38.9                           (19.5--62.6)                       78.1       (59.9--89.5)   0.782   (0.753--0.813)
  C               38.5                           (19.2--62.2)                       81.8       (65.3--91.5)   0.753   (0.724--0.783)
  S               31.4                           (14.8--54.6)                       82.2       (65.9--91.7)   0.835   (0.780--0.893)
  H               5.9                            (2.3--14.5)                        94.4       (87.6--97.6)   0.996   (0.735--1.351)

Sensitivity, specificity, and likelihood ratio negative (LRN) from the bivariate random-effects meta-analysis model. Rule is at least one of the indicated symptoms. C, current cough; H, haemoptysis; F, fever; S, sweats; W, weight loss.

*p*-Value \>0.05 for the same sensitivity of the CFSW rule and the indicated rule. All specificities are significantly different from that of the CFSW rule.

LRN, likelihood ratio negative.

The nine included studies demonstrated significant between-study heterogeneity on both sensitivity (*p*\<0.001) and specificity (*p*\<0.001) of the rule CFSW (see also [Figure 3](#pmed-1000391-g003){ref-type="fig"}). The bivariate graphic shows that six studies have study-level specificities below and three above the population average specificity. Furthermore, this rule has the highest-ranking sensitivity in eight of the nine included studies ([Table S2](#pmed.1000391.s003){ref-type="supplementary-material"}). The hierarchical summary relative operating characteristic curves ([Figure S1](#pmed.1000391.s001){ref-type="supplementary-material"}) show slightly better overall diagnostic performance of the rules CFS and CF, but our application requires the highest sensitivity possible, allowing for some tradeoffs with lower specificity. [Figure 3](#pmed-1000391-g003){ref-type="fig"} shows that three studies are outliers, and they represent studies of patients who were previously screened for TB or studies in which much of the population likely had previous TB screening (e.g., miners); this can modify the performance characteristics of the screening rule.

![Diagnostic performance of CFSW rule in the included studies.\
BREMA, bivariate random-effects meta-analysis; HSROC, hierarchical summary relative operating characteristic.](pmed.1000391.g003){#pmed-1000391-g003}

The CFSW rule has sensitivity of 90.1% (95% CI 76.3%--96.2%) and 67.1% (95% CI 41.7%--85.3%) among participants selected from clinical and community settings, respectively. Similarly the sensitivity of the rule among those who had not been previously screened for TB was higher at 88.0% (95% CI 76.1%--94.4%) compared to those who had been screened for TB at 40.5% (95% CI 16.6%--69.9%). At the 95% confidence level, the sensitivity of this rule could not be statistically distinguished from the sensitivity of the rule that substitutes haemoptysis for current cough (HFSW, 75.7% sensitive \[95% CI 53.9--89.2%\]) or the rule that drops night sweats (CFW, 74.0% sensitive \[51.7--88.3%\]). All other rules had lower sensitivity.

Regression analysis of study-level predictors revealed that studies in which TB screening was performed in clinical settings had 4.5 times the odds for a true-positive screening result compared to studies in which TB screening was performed in a community setting (95% CI 1.0--19.5). Studies of participants who had not previously been screened for TB had 10.8 times the odds for a true-positive screen (95% CI 2.4--47.8) compared with studies in which participants had previously been screened for TB. Participants with CD4 cell count \<200 cells/µl had 6.4 times the odds of a true-positive screen (95% CI 2.9--14.2). Statistically significant predictors of true-negative results include prescreening, geographic region, participant age ≥33 y, CD4 cell count \<200 cells/ml, and abnormal result on chest radiograph ([Table 4](#pmed-1000391-t004){ref-type="table"}).

10.1371/journal.pmed.1000391.t004

###### Association of study-level and individual-level predictors with the diagnostic performance of CFSW rule.

![](pmed.1000391.t004){#pmed-1000391-t004-4}

  Predictors                                                   Sensitivity (95% CI)                  Specificity (95% CI)                  
  ----------------------------------------------------------- ---------------------- ----------------------------------------------------- ---------------------------------------------------
  **Study level**                                                                                                                          
  Setting                                                           Community                                 1.0                          
                                                                     Clinical         4.45 (1.02, 19.46)[a](#nt108){ref-type="table-fn"}                    0.25 (0.06--1.01)
                                                                      Miners                           0.25 (0.02--2.51)                                   4.07 (0.44--37.68)
  Screening                                                     Prescreened for TB                            1.0                          
                                                               Not screened for TB    10.82 (2.45--47.78)[a](#nt108){ref-type="table-fn"}   0.08 (0.06--0.12)[a](#nt108){ref-type="table-fn"}
  Culture medium                                                      Solid                                   1.0                          
                                                                      Liquid                          3.41 (0.57--20.30)                                    0.33 (0.06--1.97)
  Region                                                        Sub-Saharan Africa                            1.0                          
                                                                  Southeast Asia                      4.03 (0.65--24.84)                    0.20 (0.04--1.00)[a](#nt108){ref-type="table-fn"}
  **Individual level**                                                                                                                     
  Age[b](#nt109){ref-type="table-fn"}                                 \<33 y                                  1.0                          
                                                                      ≥33 y                            1.43 (0.81--2.52)                    0.74 (0.66--0.84)[a](#nt108){ref-type="table-fn"}
  Gender                                                              Female                                  1.0                          
                                                                       Male                            1.26 (0.71--2.24)                                    1.04 (0.93--1.16)
  CD4 cell count[c](#nt110){ref-type="table-fn"}                  ≥200 cells/µl                               1.0                          
                                                                  \<200 cells/µl      6.38 (2.87--14.17)[a](#nt108){ref-type="table-fn"}    0.46 (0.38--0.57)[a](#nt108){ref-type="table-fn"}
  Abnormal chest radiograph[d](#nt111){ref-type="table-fn"}             No                                    1.0                          
                                                                       Yes                             1.36 (0.68--2.73)                    0.41 (0.30--0.57)[a](#nt108){ref-type="table-fn"}

Values in each cell indicate the odds ratio for sensitivity or specificity compared with a referent group.

*p*-value \<0.05 for null hypothesis that odds ratio  = 1.

Excludes Shah et al. [@pmed.1000391-Shah1].

Includes only studies Cain et al. [@pmed.1000391-Cain1], Shah et al. [@pmed.1000391-Shah1], Lawn et al. [@pmed.1000391-Lawn3], and Chheng et al. [@pmed.1000391-Chheng1].

Includes only studies Cain et al. [@pmed.1000391-Cain1], Lewis et al. [@pmed.1000391-Lewis1], Shah et al. [@pmed.1000391-Shah1], and Lawn et al. [@pmed.1000391-Kimerling1].

[Table 5](#pmed-1000391-t005){ref-type="table"} shows the negative predictive value and the numbers needed to screen for the CFSW rule adjusted for individual- and study-level covariates. In a setting with 5% TB prevalence among people living with HIV, the rule has a negative predictive value of 98.3% (95% CI 97.5%--98.8%) for patients screened in a clinical setting and 97.3% (95% CI 96.9%--97.7%) for patients screened in a community setting. The numbers needed to screen at the same prevalence of TB are 15 and 11 for clinical and community setting, respectively. The negative predictive value was similar in those having high (≥200) and low (\<200) CD4 count at 96.9% (95% CI 95.1%--98.0%) and 98.9% (95% CI 97.5%--99.5%), respectively (see also [Table S3](#pmed.1000391.s004){ref-type="supplementary-material"}).

10.1371/journal.pmed.1000391.t005

###### Negative predictive value (NPV) and number needed to screen (NNS) using rule CFSW in a hypothetical population of 1,000 people living with HIV stratified by study and individual level predictors.

![](pmed.1000391.t005){#pmed-1000391-t005-5}

  Participants                                    1% TB Prevalence    5% TB Prevalence   10% TB Prevalence   20% TB Prevalence                                                                                                          
  --------------------------------------------- -------------------- ------------------ ------------------- ------------------- -------------- -------------- ------ -------------- -------------- ------ -------------- -------------- ---
  **All study participants**                            99.6            (99.5--99.6)            62                 97.7          (97.4--98.0)        12        95.3   (94.6--95.9)        6         90.0   (88.6--91.3)        3        
  **All study participants excluding miners**           99.6            (99.5--99.7)            67                 97.9          (97.5--98.2)        13        95.6   (94.8--96.3)        7         90.6   (89.0--92.1)        3        
  **Setting**                                         Clinical              99.7           (99.5--99.8)             78               98.3       (97.5--98.8)    15        96.4       (94.8--97.5)    8         92.3       (89.0--94.6)   4
                                                     Community              99.5           (99.4--99.5)             55               97.3       (96.9--97.7)    11        94.5       (93.7--95.2)    5         88.5       (86.9--89.9)   3
                                                       Miners               99.2           (98.7--99.5)             38               96.1       (93.8--97.6)    8         92.2       (87.8--95.1)    4         84.0       (76.1--89.6)   2
  **Screening**                                  Nonscreened for TB         99.6           (99.5--99.7)             77               98.1       (97.5--98.5)    15        96.0       (94.9--96.9)    7         91.5       (89.2--93.3)   4
                                                 Prescreened for TB         99.3           (99.3--99.3)             36               96.5       (96.2--96.7)    7         92.8       (92.4--93.2)    4         85.1       (84.3--86.0)   2
  **Culture medium**                                   Liquid               99.6           (99.3--99.8)             75               98.2       (96.7--99.0)    15        96.2       (93.2--98.0)    7         91.9       (85.9--95.5)   3
                                                       Solid                99.5           (99.4--99.5)             57               97.3       (97.0--97.7)    11        94.6       (93.8--95.2)    6         88.5       (87.1--89.8)   3
  **Geography**                                    Southeast Asia           99.6           (99.2--99.8)             81               98,0       (95.9--99.0)    16        95,9       (91.6--98.0)    8         91.2       (83.0--95.6)   4
                                                 Sub-Saharan Africa         99.5           (99.4--99.6)             52               97.4       (97.1--97.8)    10        94.8       (94.0--95.4)    5         88.9       (87.5--90.2)   3
  **Age**                                              ≥33 y                99.6           (99.5--99.7)             63               97.8       (97.2--98.2)    12        95.4       (94.3--96.4)    6         90.3       (88.0--92.1)   3
                                                       \<33 y               99.5           (99.4--99.6)             59               97.5       (97.0--97.9)    12        94.8       (94.0--95.6)    6         89.1       (87.4--90.6)   3
  **Gender**                                            Male                99.5           (99.4--99.6)             64               97.5       (97.2--97.9)    13        95.0       (94.2--95.6)    6         89.3       (87.8--90.6)   3
                                                       Female               99.6           (99.5--99.7)             60               98.0       (97.5--98.4)    12        95.8       (94.9,96.6)     6         91.0       (89.2--92.6)   3
  **CD4 cell count**                               ≥200 cells/µl            99.4           (99.0--99.6)             80               96.9       (95.1--98.0)    16        93.6       (90.2--95.9)    8         86.7       (80.4--91.2)   4
                                                   \<200 cells/µl           99.8           (99.5--99.9)             81               98.9       (97.5--99.5)    16        97.8       (94.8--99.1)    8         95.1       (89.1--97.9)   4
  **Abnormal chest radiograph**                         Yes                 99.4           (99.0--99.6)             83               97.0       (95.2--98.2)    16        93.9       (90.3--96.2)    8         87.2       (80.6--91.8)   4
                                                         No                 99.5           (99.3--99.7)             61               97.7       (96.7--98.4)    12        95.2       (93.2--96.7)    6         89.9       (85.9--92.9)   3

Four studies [@pmed.1000391-Cain1],[@pmed.1000391-Lewis1],[@pmed.1000391-Shah1],[@pmed.1000391-Lawn3] consistently recorded information on chest radiograph, allowing screening rules with this sign to be evaluated using data from 2,805 participants The addition of abnormal chest radiographic findings into the CFSW rule increases the sensitivity to 90.6% (95% CI 66.7%--97.9%) with a specificity of 38.9% (95% CI 12.8%--73.3%), and a likelihood ratio negative of 0.242 (95% CI 0.102--0.571). Fifteen of the 23 rules included in our analysis outperform the symptom-based CFSW rule when abnormal chest radiographic findings are added ([Table S4](#pmed.1000391.s005){ref-type="supplementary-material"}).

On the basis of our meta-analysis findings and incorporating current WHO recommendations on provision of IPT, we developed a simple TB screening algorithm for public health programmes to screen people living with HIV, and, depending on the outcome of screening, to either provide IPT or evaluate patients further for TB or other diseases ([Figure 4](#pmed-1000391-g004){ref-type="fig"}).

![Algorithm for TB screening in person living with HIV in HIV prevalent and resource-constrained settings.\
\* Every person living with HIV needs to be evaluated for ART eligibility, and all settings providing care should reduce TB transmission through proper measures. \*\* Chest radiography is not required to classify patients into the TB and not-TB groups, but can be done, if available, to increase the sensitivity of screening. \*\*\* Assess for contraindications, including active hepatitis (acute or chronic), regular and heavy alcohol consumption, and symptoms of peripheral neuropathy, is required prior to initiating IPT. Past history of TB is not a contraindication for starting IPT. Tuberculin skin test may be performed as part of eligibility screening in some settings. \*\*\*\* Investigations for TB should be done in accordance with existing national guidelines.](pmed.1000391.g004){#pmed-1000391-g004}

Discussion {#s5}
==========

We found that the absence of all of current cough, fever, night sweats, and weight loss can identify a subset of people living with HIV who have low probability of having TB disease. This screening rule was superior over other candidate rules in eight of the nine studies included and had an overall favourable performance over competing rules in the hierarchical summary relative operating characteristic (HSROC) analysis. We also demonstrated that the negative predictive value of the rule was high across a range of TB disease prevalence estimates and across different population subsets, including those with low and high CD4 count, and those drawn from clinical and community settings and South African miners. We believe that these screening questions are likely to be acceptable to practitioners, because they are symptoms classically associated with TB disease.

Underdiagnosis and delayed diagnosis of TB contribute to excess mortality among people living with HIV [@pmed.1000391-Getahun2]. Similarly, concerns about the ability to reliably rule out active TB before initiating IPT have been a major barrier for wider use of this intervention. In the absence of a rapid and effective TB diagnostic tool available at the point-of-care, simple clinical algorithms must be used to screen people living with HIV for TB, dividing them into those in whom active TB is excluded and those who require further evaluation. This meta-analysis synthesizes the best available evidence for how to do this by relying on individual patient data of culture-confirmed TB cases from people living with HIV in the two regions of the world with the most severe burden of the TB and HIV dual epidemic.

The major change to existing practice would be the replacement of chronic cough with current cough as a screening question and the addition of other symptoms to standard screening. National TB programs have traditionally defined a TB "suspect" as someone with cough lasting greater than 2 or 3 wk, and designed case-finding activities to investigate up to ten TB suspects for every TB case detected [@pmed.1000391-WHO3]. However, studies included in this analysis have shown that chronic cough is highly insensitive for TB disease in people living with HIV; using this symptom as a screening rule would miss cases and contribute to diagnostic delays [@pmed.1000391-Reid1],[@pmed.1000391-Cain1]. Using the combination of symptoms that we propose, in a population of people living with HIV with a 5% TB prevalence (excluding miners), requires the investigation of 13 extra patients for every TB case detected, a ratio of TB suspects to a TB case not much different from what national TB control programmes target in the general population.

There has been ongoing debate about the importance of chest radiography in screening people living with HIV for IPT eligibility [@pmed.1000391-Mosimaneotsile1],[@pmed.1000391-Samandari1]. Our analysis showed that the addition of abnormal chest radiography findings into the screening rule of CFSW increases the sensitivity of the rule by 11.7% (90.6% versus 78.9%) with a reduction of specificity by 10.7% (49.6% versus 38.9%). However, for example at a 5% TB prevalence rate among people living with HIV, augmenting the CFSW rule with abnormal chest radiographic findings increases the negative predictive value by a margin of only 1% (98.7% versus 97.8%), albeit with the same number of cases needed to be screened. On the other hand, the addition of abnormal chest radiographic findings to the rule at TB prevalence of 20% among people living with HIV increases the negative predictive value by almost 4% (94.3% versus 90.4%) without additional cases needed to be screened. It is also worth noting that the CFSW screening rule has higher sensitivity among those who presented into a clinical setting (90%) and among those who have not been previously screened for TB (88%).

Our findings show that the utility of the proposed symptom-based screening rule have excellent performance in most settings with TB and HIV burden. However, the negative predictive value will fall in those settings with higher TB prevalence when symptom screening alone is used, as it depends on prevalence of disease. In particular settings (e.g., antiretroviral clinics with a very high TB burden [@pmed.1000391-Kranzer1]), consideration must be given to use of an algorithm that contains chest radiography, or even adding additional sensitive investigations (e.g., culture) while screening people living with HIV for TB [@pmed.1000391-Bassett1],[@pmed.1000391-Lawn4]. People living with HIV and receiving IPT should also be regularly screened for TB during their visit to a health facility or contact with health care provider so as to promptly detect active TB, if it develops. Programme managers need to weigh the financial, technical, and logistic difficulties, and patient cost and inconvenience associated with performing chest radiography or other additional sensitive investigations on all people living with HIV as part of a screening program compared with an approach that relies only on symptomatic screening.

When interpreting our results, one must bear in mind that only a few variables were common to all studies included in the meta-analysis. It is possible that the addition of one or more symptoms not included in our list of common symptoms could have improved the performance of our proposed screening rule. However, at least one study included in our meta-analysis explored over 80 million combinations of about 100 signs and symptoms and found a symptom combination (cough and fever of any duration and night sweats for 3 weeks or longer), which was similar to the one we propose as the best performing one [@pmed.1000391-Cain1]. Furthermore, questions were not asked in a uniform manner across all studies, and the reporting of symptoms can be highly dependent on factors such as the quality of the interview and interviewer, the circumstances under which questions are asked, and the social and cultural factors that shape individual perceptions of symptoms and disease [@pmed.1000391-Banerji1]. We reviewed all questions carefully with principal investigators and data managers to ensure accurate mapping of differently phrased questions to common variables. Our study relied on patients drawn from multiple countries and multiple settings, and the variation in the performance of the proposed screening rule across these different settings suggests that variation in patient self-report of symptoms is unlikely to have major impact, at least at the population level. In some studies, only one sputum specimen was collected for culture, while multiple cultures are required to maximize sensitivity. Some patients with TB may have been incorrectly classified as not having TB. Extrapulmonary TB is an important cause of morbidity and mortality in people living with HIV, but most studies included in the meta-analysis focused on screening for pulmonary TB. Young children were not included in the studies. We did not specifically look into the role of tuberculin skin test in the proposed screening rule. Ideally, the utility of the algorithm we propose, based on the screening rule from our meta-analysis, should be studied prospectively using a standardized protocol in multiple diverse sites; this is particularly important as the studies included in our analysis came from only two geographical regions of the world. Similarly, because of the time required for the data aggregation, statistical analysis, manuscript preparation, and publication, there was one potentially eligible study that was not included in our analysis [@pmed.1000391-Bassett1]. We believe that the exclusion of this single study from South Africa, a country from which we have included similar studies already, will not affect the interpretation of our data and conclusions. In the future, as more studies are reported, particularly from other regions, it will be important to repeat the meta-analysis.

Greatly improving TB screening, diagnosis, and treatment in people living with HIV will require deployment of a rapid, accurate, point-of-care TB diagnostic test. In the absence of such a test, we believe that a standardized algorithm employing symptoms, as we propose here, can improve the diagnosis and treatment of TB for people living with HIV, and by doing so would save many lives. Reliable exclusion of TB disease will facilitate safer initiation of antiretroviral therapy and will allow for broader use of IPT, which can substantially reduce TB incidence. Earlier and accurate HIV and TB screening and treatment may also help identify infectious cases earlier, thereby reducing both HIV and TB transmission. Evidence-based and internationally recommended guidelines should be used to expedite the diagnosis and treatment of TB in people living with HIV [@pmed.1000391-WHO4].
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